By clicking "Accept," you consent to cookies being stored on your device to enhance site navigation and analyze site usage.
AcceptDeny
Investor relations

Welcome to Our Investor Relations Page

Explore key financial information, reports, and updates. Stay informed about our latest developments and learn how we create value for our shareholders. Your go-to resource for all investment-related inquiries.

Press Releases
Contact Us
Investor Relations

Essential Information & Investor Relations

Here you’ll find essential financial reports, key dates, events, presentations, and analytical coverage to keep you informed about Biosergen’s latest developments and investment opportunities.

Financial Reports
Financial Calendar
Events, Presentations, Media
Analytical Coverage

Financial Reports

2024

Interim Report 2024 Q1

Swedish report
English report

Interim report 2024 Q2

Swedish report
English report
2023

Annual Report 2023

Swedish report
English report

Interim report 2023 Q1

Swedish report
English report

Interim Report 2023 Q2

Swedish report
English report

Interim report 2023 Q3

Swedish report
English report

Interim Report 2023 Q4

Swedish report
English report
2022

Annual Report 2022

Swedish report
English report

Interim Report 2022 Q1

Swedish report
English report

Interim Report 2022 Q2

Swedish report
English report

Interim Report 2022 Q3

Swedish report
English report

Interim Report 2022 Q4

Swedish report
English report
2021

Annual Report 2021

Swedish report
English report

Interim Report 2021 Q2

Swedish report
English report

Interim Report 2021 Q3

Swedish report
English report

Interim Report 2021 Q4

Swedish report
English report

Financial Calendar

Interim Report Q2
Aug 30, 2024
Interim Report Q3
Nov 8, 2024
Year end Report 2025
Mar 31, 2025

Company presentation

Company presentation

Investor One Pager

Read paper

Media

Media

Biosergen advances BSG005 antifungal drug candidate trial

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen’s CEO, Tine Olesen, came to BioStock's studio to discuss this milestone, the company’s financing and the next steps ahead.
Watch video
Watch video
Media

Investeringsguld i de ‘glemte’ sygdomme?

Der findes flere sygdomme end diabetes, hjertekarsygdomme og cancer, men investeringsmæssigt fylder de - næsten - hele debatten. Millionærklubben tjekker derfor noget af alt dét, der sjældent bliver talt om, og ser bl.a. på resistente bakterier og svampeinfektioner - medicinske problemer, der desværre ser ud til at være i hastig vækst. I studiet gør Tine Kold Olesen, CEO i Biosergen AB, lytterne klogere på sagen og chefanalytiker Lau Svenssen fra Svenssen & Tudborg tjekker investeringsmuligheder og faldgruber i biotech-investeringer.
Listen to the podcast
Listen to the podcast
Media

Investor presentation and Q&A with Carlsquare analyst 2024

View presentation
View presentation
Media

Interview with Tine Kold Olesen, CEO

How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they hope will become market leading
Read Interview
Read Interview
Media

Biosergen and Invasive Fungal Infections

I dette afsnit har vi fået besøg af CEO, Tine Kold Olesen og CFO, Niels Laursen fra virksomheden Biosergen.
Podcast
Podcast
Media

Investor PDF

Read PDF
Read PDF
Media

Biosergen and Invasive fungal infections

Fungal infections are a global threat that is becoming increasingly severe World Health Organization says.
Read Article
Read Article
Media

Biosergen vill optimera behandling av dödliga svampinfektioner

Upp till 90 procent av individer som drabbas av invasiva svampinfektioner dör under de första två veckorna
Read Article
Read Article

Analytical Coverage

Analytical Coverage

Carlsquare

Carlsquare is a global Investment bank, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 170+ employees with deep sector knowledge in all 11 GICSsectors.The senior equity research team has extensive experience in the stock market and several busines sectors. The team produces company research reports, commodity research, independent valuations and trading notes. The group has offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States.
View coverage
Analytical Coverage

Mangold

Mangold Fondkommission AB is a Swedish investmentbank offering financial services including M&A advisory, structuredfinancing, and equity research. Mangold's equity research team, MangoldInsight, aims to contribute to new investor perspectives and to increase thestock market's interest in small and medium-sized growth companies listed on Spotlight Stock Market, NGM, Nasdaq First North Growth Market, and Nasdaq Stockholm.
View coverage

Governance

Articles of Association
Current Articles of Association
Nasdaq First North Growth Market Stockholm

The company is has been listed at Nasdaq First North Growth Market, Stockholm since June 24, 2021.

Certified Adviser

Carnegie Investment Bank AB (publ)
+46 (0)73 856 42 65
certifiedadviser@carnegie.se

Auditor

PricewaterhouseCoopers AB
Torsgatan 21
113 97 Stockholm

PricewaterhouseCoopers AB is represented by Johan Engstam, State Authorised Public Accountant,

Filings / Archive
All archived filings
Largest shareholders

Largest shareholders per 2024-04-30

Contact us
Company / Name
Number of shares
Votes & holding (%)
Östersjöstiftelsen
68,120,899
47.84%
Ribbskottet Aktiebolag
20,000,000
14.05%
Rosetta Capital IV SARL
14,517,009
10.20%
Tuvedalen Limited
7,518,049
5.28%
Sum of owners with >5% ownership
110,155,957
77.37%
Others
32,231,234
26.63%
Total
142,387,191
100%

Board of Directors

Biosergen´s board has vast experience in biotech industry spanning from development to commercialization and the financial aspects of pharmaceutical industry.

Anna Ljung
Chairperson
Read more

Chairperson

Anna Ljung

0
Shares
450000
Warrants

Professional experience

Independent in relation to the company, to its senior executives and major shareholders

Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as AtheraBiotechnologies AB and Lipopetide AB and as independent technology licensingconsultant.

Currently Anna is serving as CEO of Moberg Pharma and as Board member of Saniona AB and ADDvise Group AB.

Educational background

M.Sc in Economic and Business Administration from the Stockholm School of Economics

Professional experience

Independent in relation to the company, to its senior executives and major shareholders

Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as AtheraBiotechnologies AB and Lipopetide AB and as independent technology licensingconsultant.

Currently Anna is serving as CEO of Moberg Pharma and as Board member of Saniona AB and ADDvise Group AB.

Educational background

M.Sc in Economic and Business Administration from the Stockholm School of Economics

White close buttonBlack close button
Marianne Kock
Deputy Chairperson
Read more

Deputy Chairperson

Marianne Kock

0
Shares
400000
Warrants

Professional experience

Marianne Kock has been Board member since 2021 and since 2024 Deputy Chairperson

Independent in relation to the company to its executive management and majorshareholders

Currently serves as General Manager at Ferring Pharmaceuticals’ IPCDevelopment Unit in Copenhagen.

Board member of Ferring Pharmaceutical (DK), Syntese (DK), IzvarinoPharma (Rus), NanoPharm (Rus) and Asarina (SE)

Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO),Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)

‍

Educational background

Msc, MBA

Professional experience

Marianne Kock has been Board member since 2021 and since 2024 Deputy Chairperson

Independent in relation to the company to its executive management and majorshareholders

Currently serves as General Manager at Ferring Pharmaceuticals’ IPCDevelopment Unit in Copenhagen.

Board member of Ferring Pharmaceutical (DK), Syntese (DK), IzvarinoPharma (Rus), NanoPharm (Rus) and Asarina (SE)

Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO),Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)

‍

Educational background

Msc, MBA

White close buttonBlack close button
Mattias Klintemar
Board Member
Read more

Board Member

Mattias Klintemar

34285
Shares
0
Warrants

Professional experience

Mattias Klintemar has been Boardmember since 2021.

Dependent in relation to the company and dependent in relation to its senior executives and major shareholders.

Currently Mattias Klintemar serves as Director of Investments at Östersjöstiftelsen
Has among others worked at ABG Sundal Collier and served as CEO at MorphicTechnologies, CFO at Hexaformer, Chairman of the board at Dilafor and boardmember of Moberg Pharma, Axelar, Phoniro and DBT.
Board member at Oatly, Palette Life Sciences and Velove

‍

Educational background

Mattias Klintemar holds a Bachelor’s degree in Accounting and Finance from Karlstad University.

Professional experience

Mattias Klintemar has been Boardmember since 2021.

Dependent in relation to the company and dependent in relation to its senior executives and major shareholders.

Currently Mattias Klintemar serves as Director of Investments at Östersjöstiftelsen
Has among others worked at ABG Sundal Collier and served as CEO at MorphicTechnologies, CFO at Hexaformer, Chairman of the board at Dilafor and boardmember of Moberg Pharma, Axelar, Phoniro and DBT.
Board member at Oatly, Palette Life Sciences and Velove

‍

Educational background

Mattias Klintemar holds a Bachelor’s degree in Accounting and Finance from Karlstad University.

White close buttonBlack close button
Robert Molander
Board member
Read more

Board member

Robert Molander

0
Shares
350000
Warrants

Professional experience

Independent in relation to the company to its executive management and major shareholders

Robert has more than 25 years of expertise in life science commercialization as Senior executive and advisor primarily based in the United States.

Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at InfantBacterial Therapeutics AB and Trialbee AB and a board member of InfantBacterial Therapeutics AB
‍

Currently Robert serves as Board member of Xspray Pharma AB of SciBase AB and is CEO of StratfoxHealthcare Group LLC

‍

Educational background

MBA from Washington University

Professional experience

Independent in relation to the company to its executive management and major shareholders

Robert has more than 25 years of expertise in life science commercialization as Senior executive and advisor primarily based in the United States.

Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at InfantBacterial Therapeutics AB and Trialbee AB and a board member of InfantBacterial Therapeutics AB
‍

Currently Robert serves as Board member of Xspray Pharma AB of SciBase AB and is CEO of StratfoxHealthcare Group LLC

‍

Educational background

MBA from Washington University

White close buttonBlack close button

Press Releases

All Press Releases
Surgeon mask with medical equipment

Share Information

Discover the power of BSG005

Learn more about our innovative antifungal drug, BSG005. Contact Biosergen AB for further information.

Learn moreContact